

**UNITED STATES OF AMERICA  
BEFORE THE FEDERAL TRADE COMMISSION**

**COMMISSIONERS: Maureen K. Ohlhausen, Acting Chairman  
Terrell McSweeney**

<hr/>		)	
<b>In the Matter of</b>		)	
		)	
<b>BECTON, DICKINSON AND COMPANY</b>		)	<b>Docket No. C-4637</b>
<b>a corporation</b>		)	
		)	
<b>and</b>		)	
		)	
<b>C. R. BARD, INC.</b>		)	
<b>a corporation.</b>		)	
<hr/>		)	

**COMPLAINT**

Pursuant to the Clayton Act and the Federal Trade Commission Act (“FTC Act”), and its authority thereunder, the Federal Trade Commission (“Commission”), having reason to believe that Respondent Becton, Dickinson and Company (“BD”), a corporation subject to the jurisdiction of the Commission, has agreed to acquire all of the issued and outstanding shares of



market share of approximately 98% in the United States. Two other firms comprise the small balance of the relevant market. The Acquisition would substantially increase concentration in the already highly concentrated U.S. market for tunneled home drainage catheter systems.

8. Respondents BD and Bard are the two largest manufacturers of soft tissue core needle biopsy devices in the United States. Bard and BD have the number one and number two market share positions, respectively. Post-merger, the Respondents would have a combined market share of approximately 60% or greater in the United States. Other firms in this market have consideracv0 Td (.)Tj 0.26 0 Td ( )T[(ap)1oR.26 0 0 Td ( )Tj -0.004 T8.7( )]hi0-5(h)-2 - T8.Tj 0.26

**WHEREFORE, THE PREMISES CONSIDERED,** the Federal Trade Commission on this twenty-second day of December 2017, issues its Complaint against said Respondents.

By the Commission.

Donald S. Clark  
Secretary

SEAL: